Introducing vedolizumab to clinical practice: who, when and how? by Bryant, R, Sandborn, W, Travis, S

“…Background Vedolizumab (VDZ), a humanized monoclonal antibody that selectively targets alpha4beta7 integrin, is approved for use in inflammatory bowel disease (IBD). …”

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience by Feagan, B, Bhayat, F, Khalid, J, Palo, W, Blake, A, Shetzline, M, Travis, S

“…Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. …”

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease by Travis, S, Ungaro, R, Blake, A, Bhayat, F, Card, T

“…Vedolizumab is a gut-selective antibody to α4β7 integrin approved for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in adult patients. …”

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections by Bhayat, F, Blake, A, Travis, S

“…Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin, selectively blocking gut-specific lymphocyte trafficking. …”

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. by Van Assche, G, Lewis, J, Lichtenstein, G, Loftus, E, Ouyang, Q, Panes, J, Siegel, C, Sandborn, W, Travis, S, Colombel, J

“…There is a specific risk of the rare γ δ hepatosplenic lymphoma that appears to have a predeliction for young males on combination therapy. The α4 integrin antagonist natalizumab also carries a specific risk of progressive multifocal leucoencephalopathy and reactivation of JC virus infection. …”

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. by Bye, W, Jairath, V, Travis, S

“… <h4>Background</h4> <p>Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. …”

Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data by Card, T, Ungaro, R, Bhayat, F, Blake, A, Hantsbarger, G, Travis, S

“…<br><strong>Background: </strong>Vedolizumab is a gut‐selective antibody to α4β7 integrin approved to treat moderate‐to‐severe Crohn's disease and ulcerative colitis in adults. …”

The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data by Cohen, R, Bhayat, F, Blake, A, Travis, S

“…<p><strong>Background and Aims</strong> Vedolizumab is a gut-selective antibody to α₄β₇ integrin approved to treat moderate-to-severe ulcerative colitis and Crohn’s disease in adults. …”

Interfering with leukocyte trafficking in Crohn's disease by Biswas, S, Bryant, R, Travis, S

“…Drugs target the interaction between lymphocytes and endothelial cells via integrins and their ligand cellular adhesion molecules. …”